Insights

Comprehensive Service Portfolio Pharmaron offers an extensive range of research, development, and manufacturing services across various therapeutic modalities including small molecules, biologics, and cell and gene therapies. This broad service spectrum presents numerous opportunities for CRO and CDMO partnerships throughout the entire drug lifecycle.

Strategic Technological Innovations The company's recent investments in advanced technologies such as Organ-on-a-Chip (OOC) systems and large-scale mRNA and gene therapy manufacturing facilities highlight its focus on cutting-edge solutions, making it an attractive partner for innovators seeking to accelerate novel therapeutic development.

Global Expansion & Asset Investment Pharmaron’s significant investments, including a $190 million facility in the UK and strategic acquisitions like the Liverpool CGT facility from AbbVie, underscore its capacity for large-scale manufacturing and geographic expansion, offering potential collaborations for clients aiming for global development and production.

Strong Industry Partnerships Recent collaborations with organizations like CN Bio and partnerships with China Medical Systems demonstrate Pharmaron’s active engagement in advancing innovative R&D platforms and expanding its influence in the Asia-Pacific region, opening pathways for strategic alliances and joint ventures.

Financial Stability & Growth With revenue estimates between one and ten billion dollars and substantial funding of over half a billion dollars, Pharmaron exhibits robust financial health, enabling capacity for large-scale projects and long-term collaborations, making it a reliable partner for large pharmaceutical companies and biotech innovators.

Pharmaron Tech Stack

Pharmaron uses 8 technology products and services including ICP-MS, Google Ads Conversion Tracking, Adobe, and more. Explore Pharmaron's tech stack below.

  • ICP-MS
    Advanced Analytics And Data Science
  • Google Ads Conversion Tracking
    Analytics
  • Adobe
    Audio, Video, Graphics
  • MySQL
    Database
  • NetSuite
    E-commerce
  • BugHerd
    Issue Trackers
  • Yoast SEO Premium
    Search Engines
  • Yoast SEO
    Search Engines

Media & News

Pharmaron's Email Address Formats

Pharmaron uses at least 1 format(s):
Pharmaron Email FormatsExamplePercentage
First.Last@pharmaron.comJohn.Doe@pharmaron.com
95%
FLast@pharmaron.comJDoe@pharmaron.com
3%
Last@pharmaron.comDoe@pharmaron.com
1%
First@pharmaron.comJohn@pharmaron.com
1%

Frequently Asked Questions

What is Pharmaron's stock symbol?

Minus sign iconPlus sign icon
Pharmaron is a publicly traded company; the company's stock symbol is 3759.HK.

What is Pharmaron's official website and social media links?

Minus sign iconPlus sign icon
Pharmaron's official website is pharmaron.com and has social profiles on LinkedInCrunchbase.

How much revenue does Pharmaron generate?

Minus sign iconPlus sign icon
As of December 2025, Pharmaron's annual revenue is estimated to be $5B.

What is Pharmaron's SIC code NAICS code?

Minus sign iconPlus sign icon
Pharmaron's SIC code is 8731 - Commercial Physical and Biological Research NAICS code is 3254 - Pharmaceutical and Medicine Manufacturing.

How many employees does Pharmaron have currently?

Minus sign iconPlus sign icon
As of December 2025, Pharmaron has approximately 10K employees across 5 continents, including EuropeNorth AmericaAsia. Key team members include Chief Medical Officer: H. L. 李.Chief Financial Officer: R. D.Chief Business Officer: K. L.. Explore Pharmaron's employee directory with LeadIQ.

What industry does Pharmaron belong to?

Minus sign iconPlus sign icon
Pharmaron operates in the Pharmaceutical Manufacturing industry.

What technology does Pharmaron use?

Minus sign iconPlus sign icon
Pharmaron's tech stack includes ICP-MSGoogle Ads Conversion TrackingAdobeMySQLNetSuiteBugHerdYoast SEO PremiumYoast SEO.

What is Pharmaron's email format?

Minus sign iconPlus sign icon
Pharmaron's email format typically follows the pattern of First.Last@pharmaron.com. Find more Pharmaron email formats with LeadIQ.

How much funding has Pharmaron raised to date?

Minus sign iconPlus sign icon
As of December 2025, Pharmaron has raised $588M in funding. The last funding round occurred on Nov 22, 2019 for $588M.

When was Pharmaron founded?

Minus sign iconPlus sign icon
Pharmaron was founded in 2004.

Pharmaron

Pharmaceutical ManufacturingBeijing, China10001+ Employees

Pharmaron: Global Life Sciences Services Provider
Stock Code: 300759.SZ/3759.HK

Founded in 2004, Pharmaron is a premier life sciences service provider that offers a broad spectrum of research, development, and manufacturing service capabilities throughout the entire drug discovery, preclinical, and clinical development process across multiple therapeutic modalities, including small molecules, biologics, and CGT products. 

Pharmaron’s Comprehensive CRO & CDMO Services 
•	Synthetic, Medicinal, and Analytical Chemistry Services
•	Biology Services (e.g., in vitro screening, structural biology, biomarkers)
•	DMPK Services (e.g., in vitro ADME, in vivo PK, PKPD, mass balance)
•	Pharmacology Services (e.g., in vivo pharmacology, animal disease models, immunotoxicity)
•	Drug Safety Assessment Services (e.g., toxicology, safety pharmacology, genetic toxicology)
•	Radiochemistry and Isotopically Labelled Metabolism Services (e.g., 14C/Carbon-14 radiosynthesis, 3H/tritium radiosynthesis, QWBA, mARG)
•	CMC Services (e.g., API manufacturing, process chemistry, formulation development)
•	Clinical Development Services (e.g., First-in-Human [FIH], ethnobridging, microdosing Phase 0, absolute bioavailability)

Commitment to Excellence and Innovation

With a proven track record of success, Pharmaron continually invests in its people, facilities, and technologies to meet evolving scientific and regulatory demands. The company prides itself on enabling scientific breakthroughs and supporting its partners in advancing human health.
____________________________________

Learn More:  Explore Pharmaron’s services to discover how to accelerate your R&D programs. www.pharmaron.com.

________________________________________

Keywords:  CRO, CDMO, synthetic chemistry, medicinal chemistry, biology, radiochemistry, toxicology, First-in-Human, API manufacturing, PKPD, 14C radiosynthesis, discovery biologics, clinical development, small molecules, biologics, cell and gene therapy (CGT) products

Section iconCompany Overview

SIC Code
8731 - Commercial Physical and Biological Research
Stock Symbol
3759.HK
NAICS Code
3254 - Pharmaceutical and Medicine Manufacturing
Founded
2004
Employees
10001+

Section iconFunding & Financials

  • $588M

    Pharmaron has raised a total of $588M of funding over 4 rounds. Their latest funding round was raised on Nov 22, 2019 in the amount of $588M.

  • $1B$10B

    Pharmaron's revenue is estimated to be in the range of $1B$10B

Section iconFunding & Financials

  • $588M

    Pharmaron has raised a total of $588M of funding over 4 rounds. Their latest funding round was raised on Nov 22, 2019 in the amount of $588M.

  • $1B$10B

    Pharmaron's revenue is estimated to be in the range of $1B$10B

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.